Masimo Archives - Page 6 of 7 - Medical Design Sourcing

Masimo reports a Street-beating Q4

Masimo (NSDQ:MASI) posted fourth-quarter results today that beat the consensus forecast on Wall Street, issuing 2021 guidance that also exceeds analysts’ expectations.

The Irvine, Calif.–based maker of noninvasive patient monitoring technologies and sensors reported profits of $70.7 million, or $1.21 per share, on sales of $295.1 million for the three months ended Jan. 2, 2021, boosting the bottom line by a third and the top line by 19.2% compared with Q4 2019.

Adjusted to exclude one-time items, earnings per share were 98¢, 12¢ ahead of The Street, where analysts were looking EPS of 86¢ on sales of $287.45 million.

Masimo over the past year has been an important provider of pulse oximeters and other monitoring equipment that health providers and people in general needed to navigate the COVID-19 pandemic.

“Throughout 2020, as our customers on the front lines responded to this crisis and rose to the challenge, so did our team. We have invest…

Medtronic touts newborns study involving its Nellcor pulse oximetry tech

Medtronic (NYSE:MDT) announced today that study results showed superiority for its Nellcor pulse oximeter against technology from Masimo (NSDQ:MASI).

Fridley, Minn.-based Medtronic’s Nellcor bedside SpO2 patient monitoring system was compared with the Masimo Radical-7 pulse co-oximeter with both set at the highest sensitivity for electrocardiography (ECG) monitoring following the delivery of 60 term newborns by Caesarian section, according to a news release.

The study results showed that all 60 newborns presented a stable signal with the Nellcor device but only 55 newborns presented a stable signal with the Masimo pulse oximeter. Of the 55 newborns from which a stable signal was obtained by both devices, the average time to stable signal came in at 15 seconds for the Nellcor and 27 seconds for the Radical-7.

Results from the study, which was conducted at the Rabin Medical Center in Israel, were published online in the Journal of Perinatology. Medtr…

MedTech 100 roundup: Index rebounds from dip with another all-time high

The end of January saw the first major dip for the medtech industry but the beginning of February brought yet another peak.

MassDevice‘s MedTech 100 index ended the week (Feb. 5) at 108.23 points, marking a 4% rise from the 104.05-point mark set at the end of the previous week (Jan. 29).

The final mark for the week sets an all-time best for the index, which had previously reached 106.81 points on Jan. 8, then 107.4 points on Jan. 20. The rise has been remarkable, considering the index had never reached even the 100-point mark before November 2020.

Medtech’s latest rise means the index has risen 17.2% from the pre-COVID-19 pandemic high of 92.32, set on Feb. 19, 2020. Additionally, the industry has very much rebounded from its lowest place, a 62.13-point mark at the start of the pandemic on March 23, 2020. Since that point, the industry has jumped 74.2%.

Here are some of the best-performing medtech stocks from 2020.

Medtech’s performanc…

Masimo completes Lidco acquisition

Masimo (NSDQ:MASI) announced that it successfully completed the previously announced acquisition of Lidco for $40.1 million.

Irvine, Calif.-based Masimo acquired 100% of Lidco, a provider of advanced hemodynamic monitoring solutions, on Feb. 2, 2021. Lidco was de-listed from the AIM submarket of the London Stock Exchange on Jan. 11 and will be re-registered by Masimo as a UK-based private subsidiary, according to a news release.

Masimo and Lidco confirmed in a November announcement that they agreed on the terms of a recommended cash offer to be made by Masimo for the entire issued and to be issued share capital of Lidco, totaling the $40.1 million (£31.1 million) as shares are valued at about 15¢ (£0.12) per share.With a market capitalization of about $12 billion, according to the November announcement, Masimo is acquiring in Lidco a hemodynamic monitoring device maker that targets critical care and high-risk surgical patients with primary markets in the U.S. …

Masimo launches iSirona connectivity hub

Masimo (NSDQ:MASI) announced today that it commenced the global launch of the iSirona medical device connectivity hub.

Irvine, Calif.-based Masimo’s iSirona hub is designed to maximize interoperability across care, with efficiency in physically connecting up to six medical devices at the bedside and automatically routing the data to the company’s Hospital Automation platform.

Masimo Root, a patient monitoring and connectivity platform, supplements iSirona to help ensure that all patient data is accurately and efficiently captured and presented to clinicians in suitable ways, according to a news release.

iSirona includes a multi-slotted mounting bracket so it can be fixed in a room or mounted directly to a mobile medical device, such as a ventilator, with an onboard rechargeable battery and local storage that allow continued operation and data buffering for up to two hours in the event of a power outage or loss of network connectivity.

…

These medtech stocks performed the best in 2020

(From Ishant Mishra on Unsplash)

While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward.

Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while pivoting to artificial-intelligence-based and remote care.

Companies like Moderna arose from nowhere, climbing from a share price of $19.52 to $104.47 over the course of the year as it established itself as a frontronner in the race to get a COVID-19 vaccine to the public, eventually becoming the second vaccine authorized in the U.S.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has hit new heights over the course of 2020, indicating the upward trajectory of the industry. Over the course of the year, the index grew from a total of $86.8…

These medtech stocks performed the best in 2020

(From Ishant Mishra on Unsplash)

While 2020 did not go as planned for anyone, with the twists and turns came opportunities for medtech companies to power forward.

Innovations came both as a result of the COVID-19 pandemic and perhaps in spite of the challenges brought on by the virus, highlighted by the increased efforts to produce vaccines and testing while pivoting to artificial-intelligence-based and remote care.

Companies like Moderna arose from nowhere, climbing from a share price of $19.52 to $104.47 over the course of the year as it established itself as a frontronner in the race to get a COVID-19 vaccine to the public, eventually becoming the second vaccine authorized in the U.S.

MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — has hit new heights over the course of 2020, indicating the upward trajectory of the industry. Ove…

FDA clears Masimo oximetry device

Masimo this week announced that its O3 Regional Oximetry received expanded FDA clearance.

The expanded use covers monitoring somatic tissue oxygenation saturation in all patient populations and monitoring relative changes in hemoglobin, oxyhemoglobin and deoxyhemoglobin in adult brains. O3 is also now indicated for use in both cerebral and somatic applications.

The oximetry device uses O3 multi-wavelength sensors and O3 Regional Oximetry near-infrared spectroscopy technology to provide regional or tissue hemoglobin oxygen saturation.

“There is a growing interest in the use of somatic NIRS owing to the association of cerebral and somatic desaturation with unfavorable outcomes in shock states. As an addition to O3 cerebral oximetry, the somatic component could serve as an earlier warning of impaired tissue perfusion. Somatic NIRS has been validated as a monitor of peripheral perfusion and shows an excellent correlation with peripheral perfusion compa…

FDA clears Masimo index to better track ventilated patients

Masimo (NSDQ:MASI) announced today that it received FDA clearance for its PVi for fluid responsiveness indication in ventilated adult patients.

PVi (pleth variability index) now has indication as a continuous, non-invasive, dynamic indicator of responsiveness in select populations of mechanically ventilated adult patients, as it measures dynamic changes in the perfusion index that occur during the respiratory cycle, according to a news release.

Irvine, Calif.-based Masimo’s PVi is available alongside its SET pulse oximetry and Rainbow pulse co-ocimetry on a variety of sensors, using a proprietary algorithm based on the relative variability of the pleth waveform.

In an 18,716-patient study in France, researchers found that using PVi alongside Masimo’s SpHb continuous hemoglobin monitoring technology led to earlier transfusion and fewer units of blood transfused, as well as a 33% lower mortality rate 30 days after surgery, which trickled down t…

Masimo providing pulse oximeters to monitor NBA players

Masimo (NSDQ:MASI) announced today that it entered into a partnership with the National Basketball Association to become its official supplier of pulse oximetry.

The NBA is scheduled to return to competitive play tonight after going through steps to maintain safety in a “bubble”-style camp in Orlando, Fla. with 22 teams in an effort to ensure safety during the COVID-19 pandemic. League play has been suspended since March 11 when Utah Jazz player Rudy Gobert tested positive for the virus.

Since the teams arrived to the bubble on July 7, and for the remainder of their stay, each resident will measure oxygen saturation, pulse rate and respiration rate daily as part of the league’s health and safety protocols.

Irvine, Calif.-based Masimo is set to supply the league with its MightySat fingertip pulse oximeter on the Orlando campus. The MightySat device uses Masimo’s hospital-grade SET measure-through motion and low perfusion pulse oxim…

Masimo debuts patient-info platform

Masimo (NSDQ:MASI) this week launched its UniView: 60 Hospital Automation platform.

The platform aggregates and displays pertinent patient information on a display outside of a patient’s room. It allows clinicians to familiarize themselves with each patient’s case at the hospital room door in 60 seconds or less before physically seeing a patient.

The information included in the UniView: 60 include the patient’s risk of falling, environmental warnings, lab results, prescription history, radiological images, monitoring data and more. The system connects to various hospital information systems to display up to date information outside of the patient room to increase clinical efficiency.

“We’re delighted to announce UniView: 60 and be able to deploy it at one of our excellent local institutions, the University of California Irvine Medical Center. We’re proud to have been able to help UCI as they seek to build the hospital of the future. Wit…

Masimo announces drug-free opioid-withdrawal device

Masimo (NSDQ:MASI) announced that it received FDA de novo classification for its Bridge neuromodulation-based opioid withdrawal device.

Bridge uses neuromodulation to aid in reducing the symptoms associated with opioid withdrawal. Irvine, Calif.-based Masimo touts it as the first evidence-based, drug-free, non-surgical device of its kind.

The wearable, single-patient-use, percutaneous neurostimulator fits behind the ear and applies gentle electrical impulses to branches of the cranial nerves around the ear, reducing heightened neuron activity associated with opioid withdrawal symptoms. It can be easily applied by a healthcare professional in a non-surgical procedure and doesn’t interfere with normal daily activities.

Bridge aims to reduce the withdrawal symptoms to help patients with opioid-use disorder (OUD) transition away from opioids into an appropriate treatment program. Masimo said in a news release that the device was found to reduce opioid …